< img loading="lazy"class="size-large wp-image-461591"data-cfsrc="https://medcitynews.com/uploads/2019/06/GettyImages-1029077200-600x400.jpg"alt=""width="600"height="400"srcset=" https://medcitynews.com/uploads/2019/06/GettyImages-1029077200-600x400.jpg 600w, https://medcitynews.com/uploads/2019/06/GettyImages-1029077200-300x200.jpg 300w, https://medcitynews.com/uploads/2019/06/GettyImages-1029077200.jpg 724w"sizes="(max-width: 600px)100vw, 600px"> Another INVEST Precision Medicine conference has actually reoccured. At the centerpiece of the dicussions was the start-up pitch contest, Pitch Perfect. Ten companies provided an introduction of their businesses in a health IT and a life science track. Two winners emerged. Here’s a take a look at who won and why.
The winner of Health IT track is: Intellihealth
Intellihealth is a medical innovation business changing the understanding and treatment of obesity. Constructed on 30 years of scientific experience, our data-driven technology allows us to take on the obesity epidemic at scale by equipping any medical service provider with a comprehensive, turnkey solution for dealing with patients with obesity either from another location or in-person. Our software incorporates with EHRs to improve outcomes and drive expense savings by enhancing the medical diagnosis and customizing, prescriptive procedure, and thorough treatment plan to treat weight problems as an illness. Companies take advantage of new profits through more effective patient interactions and optimized billing, while payers and self-insured organizations accomplish significant health-related cost savings through a healthier workforce.
Speaker: Katherine Saunders, MD, co-founder and Senior Medical Officer
Head office: San Francisco, CA
The judges for the Health IT track consisted of:
Ten companies presented an introduction of their organizations in a health IT and a life science track. Built on 30 years of clinical experience, our data-driven technology permits us to take on the obesity epidemic at scale by equipping any medical provider with an extensive, turnkey service for dealing with patients with weight problems either remotely or in-person. Memory loss impacts over 20 million Americans with traumatic brain injury and degenerative disease, resulting in considerable reductions in performance and quality of life. Nia’s proprietary medical gadget platform makes use of brain sensing and artificial intelligence to develop a personalized treatment for each patient based upon their special pattern of brain activity. Congratulations, Intellihealth and Nia Therapeutics.
Here’s why the judges selected Nia Therapeutics:
“We reached the choice after prolonged deliberation,” stated Dong. “It has actually been based mainly around the business generating preliminary hints of medical effectiveness which somewhat de-risks the item and the big market opportunity they are pursuing.”
In the coming weeks, we’ll publish editorial profiles of each of these business on our site.
Congratulations, Intellihealth and Nia Therapeutics. Thanks to all of the judges and start-ups who participated!
Photo: Getty Images
Jackson shared why the judges selected Intellihealth, in an emailed statement.
“Intellihealth stood apart when Dr. Saunders right away attended to the issue her business is working to fix, the patient requirement, and how the platform will scale,” she said.
The winner of the life sciences track is: Nia Therapeutics
Nia Therapeutics is establishing implantable brain stimulation gadget for the treatment of amnesia. Memory loss impacts over 20 million Americans with traumatic brain injury and degenerative illness, resulting in significant declines in performance and lifestyle. Nia’s proprietary medical device platform makes use of brain picking up and synthetic intelligence to develop a customized treatment for each patient based upon their special pattern of brain activity. Its innovation was established at the University of Pennsylvania with $24 million in financing from DARPA. Its team has demonstrated proof of concept of its ability to improve human memory in neurosurgical patients. Nia’s first clinical target is amnesia due to distressing brain injury, a $32 billion whitespace market.
Speaker:Dan Rizutto, PhD, CEO
Head office:Philadelphia, Pennsylvania
The judges for the life science track were: